Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

1.

Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity.

Kang E, Yun CO.

BMB Rep. 2010 Dec;43(12):781-8. doi: 10.5483/BMBRep.2010.43.12.781. Review.

PMID:
21189153
[PubMed - indexed for MEDLINE]
Free Article
2.

Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.

Gao JQ, Eto Y, Yoshioka Y, Sekiguchi F, Kurachi S, Morishige T, Yao X, Watanabe H, Asavatanabodee R, Sakurai F, Mizuguchi H, Okada Y, Mukai Y, Tsutsumi Y, Mayumi T, Okada N, Nakagawa S.

J Control Release. 2007 Sep 11;122(1):102-10. Epub 2007 Jun 21.

PMID:
17628160
[PubMed - indexed for MEDLINE]
3.

Utilizing adenovirus vectors for gene delivery in cancer.

Kasala D, Choi JW, Kim SW, Yun CO.

Expert Opin Drug Deliv. 2014 Mar;11(3):379-92. doi: 10.1517/17425247.2014.874414. Epub 2014 Jan 7. Review.

PMID:
24392755
[PubMed - indexed for MEDLINE]
4.

Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.

Yao X, Yoshioka Y, Morishige T, Eto Y, Watanabe H, Okada Y, Mizuguchi H, Mukai Y, Okada N, Nakagawa S.

Gene Ther. 2009 Dec;16(12):1395-404. doi: 10.1038/gt.2009.95. Epub .

PMID:
19641532
[PubMed - indexed for MEDLINE]
5.

Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration.

Yao X, Yoshioka Y, Morishige T, Eto Y, Narimatsu S, Mizuguchi H, Mukai Y, Okada N, Nakagawa S.

Biol Pharm Bull. 2010;33(6):1073-6.

PMID:
20522982
[PubMed - indexed for MEDLINE]
Free Article
6.

[Development of pegylated adenovirus vector for cancer gene therapy].

Eto Y, Yoshioka Y, Asavatanabodee R, Mizuguchi H, Mukai Y, Okada N, Nakagawa S.

Yakugaku Zasshi. 2008 Dec;128(12):1733-42. Review. Japanese.

PMID:
19043292
[PubMed - indexed for MEDLINE]
Free Article
7.

Two key challenges for effective adenovirus-mediated liver gene therapy: innate immune responses and hepatocyte-specific transduction.

Descamps D, Benihoud K.

Curr Gene Ther. 2009 Apr;9(2):115-27. Review.

PMID:
19355869
[PubMed - indexed for MEDLINE]
8.

Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.

Nielsen LL, Gurnani M, Syed J, Dell J, Hartman B, Cartwright M, Johnson RC.

Hum Gene Ther. 1998 Mar 20;9(5):681-94.

PMID:
9551616
[PubMed - indexed for MEDLINE]
9.

Development of PEGylated adenovirus vector with targeting ligand.

Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S.

Int J Pharm. 2008 Apr 16;354(1-2):3-8. Epub 2007 Aug 24. Review.

PMID:
17904316
[PubMed - indexed for MEDLINE]
10.

Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.

Li X, Jung C, Liu YH, Bae KH, Zhang YP, Zhang HJ, Vanderputten D, Jeng MH, Gardner TA, Kao C.

J Gene Med. 2006 Jun;8(6):679-89.

PMID:
16570242
[PubMed - indexed for MEDLINE]
11.

Current targeting strategies for adenovirus vectors in cancer gene therapy.

Yao XL, Nakagawa S, Gao JQ.

Curr Cancer Drug Targets. 2011 Sep;11(7):810-25. Review.

PMID:
21762081
[PubMed - indexed for MEDLINE]
12.

Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy.

Park Y, Kang E, Kwon OJ, Hwang T, Park H, Lee JM, Kim JH, Yun CO.

J Control Release. 2010 Nov 20;148(1):75-82. doi: 10.1016/j.jconrel.2010.06.027. Epub 2010 Jul 15.

PMID:
20637814
[PubMed - indexed for MEDLINE]
13.

Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects.

Seiler MP, Cerullo V, Lee B.

Curr Gene Ther. 2007 Oct;7(5):297-305. Review.

PMID:
17979676
[PubMed - indexed for MEDLINE]
14.

Advances towards targetable adenovirus vectors for gene therapy.

Einfeld DA, Roelvink PW.

Curr Opin Mol Ther. 2002 Oct;4(5):444-51. Review.

PMID:
12435045
[PubMed - indexed for MEDLINE]
15.

Use of protamine to augment adenovirus-mediated cancer gene therapy.

Lanuti M, Kouri CE, Force S, Chang M, Amin K, Xu K, Blair I, Kaiser L, Albelda S.

Gene Ther. 1999 Sep;6(9):1600-10.

PMID:
10490770
[PubMed - indexed for MEDLINE]
Free Article
16.

Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.

Benihoud K, Esselin S, Descamps D, Jullienne B, Salone B, Bobé P, Bonardelle D, Connault E, Opolon P, Saggio I, Perricaudet M.

Gene Ther. 2007 Mar;14(6):533-44. Epub 2006 Nov 16. Erratum in: Gene Ther. 2007 Mar;14(6):551.

PMID:
17109009
[PubMed - indexed for MEDLINE]
17.

Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.

Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R, Liao H, Zhao HY, Zhang Y, Guan ZZ, Zhang L.

Cancer Gene Ther. 2009 Sep;16(9):723-30. doi: 10.1038/cgt.2009.19. Epub 2009 Apr 10.

PMID:
19363470
[PubMed - indexed for MEDLINE]
18.

Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.

Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG.

Mol Ther. 2002 Aug;6(2):287-97.

PMID:
12349828
[PubMed - indexed for MEDLINE]
19.
20.

Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys.

Haegel-Kronenberger H, Haanstra K, Ziller-Remy C, Ortiz Buijsse AP, Vermeiren J, Stoeckel F, Van Gool SW, Ceuppens JL, Mehtali M, De Boer M, Jonker M, Boon L.

Gene Ther. 2004 Feb;11(3):241-52.

PMID:
14737083
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk